STOCKHOLM, SWEDEN / ACCESSWIRE / April 11, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMDS and the Trustee of Coala-Life Group AB Estate will extend the closing date to April 12th.
PMDS and the Trustee of Coala-Life Group AB Estate continue to finalise key specifications of the assets before signing the Transfer Agreement. The agreement is anticipated to be signed on April 11th.
For additional information, please contact
Myles Murray, CEO
Phone: +353 86 887 4994
E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com
The Company’s Certified Adviser is Redeye.
Information about PMDS
PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital and homecare setting. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company’s knowledge, the world’s only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company’s shares are listed on Nasdaq First North Growth Market (STO: PMDS).
Attachments
SOURCE: PMD Device Solutions
View the original press release on accesswire.com
Organic growth: Revenues +2.8%, adjusted EBITDA +5.9%Capacity expansion in the Americas, Europe and Asia progresses…
- HRZN Originates $33.5 Million of New Loans in Q1 - - HRZN Ends Quarter…
athenahealth’s cloud-based suite of EHR, RCM, and patient engagement solutions empowers ZoomCare to scale and…
Cedars-Sinai Connect Expands Virtual Healthcare Services After Initial Success Treating Thousands of California AdultsLOS ANGELES--(BUSINESS…
Enhanced AI and analytics capabilities will help ACOs meet eCQM guidelines and navigate the changes…
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and…